Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis

Published:2022-04-08 Issue:1 Volume:37 Page:6-16
ISSN:0950-222X
Container-title:Eye
language:en
Short-container-title:Eye

Author:

Rosenberg Daniel,Deonarain Deven M.,Gould Jonah,Sothivannan Amirthan^ORCID,Phillips Mark R.,Sarohia Gurkaran S.^ORCID,Sivaprasad Sobha,Wykoff Charles C.,Cheung Chui Ming Gemmy^ORCID,Sarraf David,Bakri Sophie J.,Chaudhary Varun^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology

Link

https://www.nature.com/articles/s41433-022-02020-7.pdf

Reference40 articles.

1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.

2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl J Med. 2006;355:1432–44.

3. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.

4. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143:679–80.

5. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43–58.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration;International Ophthalmology;2024-09-05

2. Cochrane Corner: Anti-vascular endothelial growth factor biosimilar for macular degeneration;Eye;2024-07-19

3. Switching from a Fixed Monthly Aflibercept Regimen to Bi-Monthly Brolucizumab in Refractory Cases of Neovascular Age-Related Macular Degeneration;Journal of Clinical Medicine;2024-06-12

4. Factors Involved in Anti-VEGF Treatment Decisions for Neovascular Age-Related Macular Degeneration: Insights from Real-World Clinical Practice;Clinical Ophthalmology;2024-06

5. Home Optical Coherence Tomography Monitoring for Neovascular Age-Related Macular Degeneration: Transformative Technology or Cool Toy?;Ophthalmology and Therapy;2024-05-05